Ignite Creation Date:
2024-05-06 @ 6:46 PM
Last Modification Date:
2025-12-17 @ 3:37 AM
Study NCT ID:
NCT05772091
Status:
None
Last Update Posted:
2024-03-28 00:00:00
First Post:
2023-03-06 00:00:00
Brief Title:
Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach
Sponsor:
Pr Nicolas GIRERD
Organization:
Central Hospital, Nancy, France
Study Overview
Official Title:
Valeur Pronostique Dans Une Population d'Amylose Cardiaque Des paramètres échocardiographiques basée Sur Une Approche d'Apprentissage Automatique
Status:
None
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTR-AI
Brief Summary:
Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None